This program focuses on the design of new small molecules aimed at high-value oncology targets that remain poorly served by existing therapies, including targets that have proven difficult to address with conventional approaches.

Rather than working only from approved or existing agents, this track uses Altura's AI reasoning platform to generate and prioritize novel chemical matter, then narrows large computational candidate sets down to a small number of prioritized hypotheses through structure-, selectivity-, and developability-aware filtering.

Prioritized candidates advance only through staged, human-relevant validation under Altura's scientific governance model, where computational predictions are tested against experimental ground truth before a program moves forward.

Because these are new chemical entities, the work is also designed to create defensible, ownable intellectual property where the science supports it. Specific targets, chemical structures, and program details are held confidential and shared selectively under appropriate agreements.